Knight Therapeutics   Report issue

Contributed to NME For profit Phase 2
Founded: Westmount Quebec Canada (1995)
Status: No NME R&D (1995)

Organization Overview

First Clinical Trial
2010
NCT01050907
First Marketed Drug
2014
miltefosine (impavido)
First NDA Approval
2014
miltefosine (impavido)
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Knight Therapeutics (USA) Inc | KNIGHT THERAPS